Loss of junctophilin‐3 contributes to huntington disease‐like 2 pathogenesis

Huntington disease‐like 2 (HDL2) is a progressive, late onset autosomal dominant neurodegenerative disorder, with remarkable similarities to Huntington disease (HD). HDL2 is caused by a CTG/CAG repeat expansion. In the CTG orientation, the repeat is located within the alternatively spliced exon 2A of junctophilin‐3 (JPH3), potentially encoding polyleucine and polyalanine, whereas on the strand antisense to JPH3, the repeat is in frame to encode polyglutamine. The JPH3 protein product serves to stabilize junctional membrane complexes and regulate neuronal calcium flux. We have previously demonstrated the potential pathogenic properties of JPH3 transcripts containing expanded CUG repeats. The aim of this study was to test the possibility that loss of JPH3 expression or expanded amino acid tracts also contribute to HDL2 pathogenesis.

[1]  M. Iino,et al.  Junctophilins: a novel family of junctional membrane complex proteins. , 2000, Molecular cell.

[2]  Jack W. Tsao,et al.  What's wrong with my mouse: Behavioral phenotyping of transgenic and knockout mice, J. Crawley. Wiley-Interscience, Hoboken, NJ (2007), 523 pages, $99.95 , 2008 .

[3]  I. Kanazawa,et al.  Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: applying to quantification of protein components of the aggregates. , 2000, Biochemical and biophysical research communications.

[4]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[5]  A. Krause,et al.  Huntington's disease: genetic heterogeneity in black African patients. , 2008, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[6]  N. Hirokawa,et al.  Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice , 2000, Neuroscience Letters.

[7]  Dobrila D. Rudnicki,et al.  An Antisense CAG Repeat Transcript at JPH3 Locus Mediates Expanded Polyglutamine Protein Toxicity in Huntington's Disease-like 2 Mice , 2011, Neuron.

[8]  J. Rommens,et al.  Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy , 1998, Nature Genetics.

[9]  M. Nishi,et al.  Characterization of human junctophilin subtype genes. , 2000, Biochemical and biophysical research communications.

[10]  M. MacDonald,et al.  Insoluble TATA-binding protein accumulation in Huntington's disease cortex. , 2002, Brain research. Molecular brain research.

[11]  Kiyoshi Iwabuchi,et al.  Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias – triple-labeling immunofluorescence study , 2001, Acta Neuropathologica.

[12]  I. Imanaga,et al.  Store-operated Ca2+ entry uncoupled with ryanodine receptor and junctional membrane complex in heart muscle cells. , 2002, Cell calcium.

[13]  T. Mizutani,et al.  Cytoplasmic and nuclear polyglutamine aggregates in SCA6 Purkinje cells , 2001, Neurology.

[14]  T. Uchihara,et al.  Neuronal intranuclear hyaline inclusion disease with polyglutamine-immunoreactive inclusions , 2000, Acta Neuropathologica.

[15]  V. Willour,et al.  A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion , 2001, Annals of neurology.

[16]  T. Ebner,et al.  Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8 , 2006, Nature Genetics.

[17]  Jacqueline N. Crawley,et al.  What's Wrong With My Mouse? , 2007 .

[18]  T. Yamazaki,et al.  New molecular components supporting ryanodine receptor-mediated Ca(2+) release: roles of junctophilin and TRIC channel in embryonic cardiomyocytes. , 2009, Pharmacology & therapeutics.

[19]  S. Finkbeiner,et al.  Using antibodies to analyze polyglutamine stretches. , 2004, Methods in molecular biology.

[20]  M. Nishi,et al.  Coexpression of junctophilin type 3 and type 4 in brain. , 2003, Brain research. Molecular brain research.

[21]  C. Ross,et al.  Huntington's disease–like 2 is associated with CUG repeat‐containing RNA foci , 2007, Annals of neurology.

[22]  Masahiko Watanabe,et al.  Abnormal features in mutant cerebellar Purkinje cells lacking junctophilins. , 2007, Biochemical and biophysical research communications.

[23]  C. Ross,et al.  A Comparison of Huntington Disease and Huntington Disease-Like 2 Neuropathology , 2008, Journal of neuropathology and experimental neurology.

[24]  T. Klockgether,et al.  Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. , 2007, Biochemical and biophysical research communications.

[25]  S. Tapscott,et al.  Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. , 2005, Molecular cell.

[26]  M. Kano,et al.  Motor discoordination in mutant mice lacking junctophilin type 3. , 2002, Biochemical and biophysical research communications.

[27]  J. Jankovic,et al.  Phenotypic features of Huntington's disease‐like 2 , 2003, Movement disorders : official journal of the Movement Disorder Society.

[28]  Martin G. Reese,et al.  Application of a Time-delay Neural Network to Promoter Annotation in the Drosophila Melanogaster Genome , 2001, Comput. Chem..

[29]  J. Mysore,et al.  Huntington's disease–like 2 (HDL2) in North America and Japan , 2004, Annals of neurology.

[30]  Michael Ruogu Zhang,et al.  Computational identification of promoters and first exons in the human genome , 2002, Nature Genetics.

[31]  H. Paulson,et al.  Recruitment and the Role of Nuclear Localization in Polyglutamine-mediated Aggregation , 1998, The Journal of cell biology.

[32]  R. Dyer,et al.  Mutant protein in Huntington disease is resistant to proteolysis in affected brain , 2001, Nature Genetics.

[33]  S. Folstein,et al.  Huntington's disease gene (IT15) is widely expressed in human and rat tissues , 1993, Neuron.

[34]  C. Ross,et al.  A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease–like 2 , 2001, Nature Genetics.

[35]  Johan T den Dunnen,et al.  Strong aggregation and increased toxicity of polyleucine over polyglutamine stretches in mammalian cells. , 2002, Human molecular genetics.

[36]  J. Golden,et al.  A polyalanine tract expansion in Arx forms intranuclear inclusions and results in increased cell death , 2004, The Journal of cell biology.

[37]  P. Greengard,et al.  Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation , 1983, The Journal of cell biology.

[38]  M. Swanson,et al.  Partners in crime: bidirectional transcription in unstable microsatellite disease. , 2010, Human molecular genetics.

[39]  R. Matsuoka,et al.  Mutation of junctophilin type 2 associated with hypertrophic cardiomyopathy , 2007, Journal of Human Genetics.

[40]  D. Borchelt,et al.  Polyglutamine pathogenesis. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[41]  A. Bernstein,et al.  Mice lacking both presenilin genes exhibit early embryonic patterning defects. , 1999, Genes & development.

[42]  S. Tabrizi,et al.  Huntington's disease phenocopy syndromes , 2007, Current opinion in neurology.

[43]  R. Margolis,et al.  A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. , 2011, Human molecular genetics.

[44]  Masahiko Watanabe,et al.  Functional uncoupling between Ca2+ release and afterhyperpolarization in mutant hippocampal neurons lacking junctophilins. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Y. Agid,et al.  Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias , 1995, Nature.

[46]  S. A. Ross,et al.  A linear lattice model for polyglutamine in CAG-expansion diseases , 2002, Proceedings of the National Academy of Sciences of the United States of America.